<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220128053852N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-04</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Procedural pain and anxiety in children</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of intranasal Midazolam, oral Melatonin and distraction method in reducing stress and pain caused by intravenous cannulation in children 3 to 10 years old</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61714</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: we will use blocked randomsation. Using the Random Allocation software 2, for 4 study groups, 15 blocks of 8 were calculated for a sample size of 120 people, each person will be identified with a unique code (consisting of two letters and a Latin number). To assign the child to each of the 4 study groups, an envelope containing a unique code and treatment group will be delivered to the child's parents. The project associate nurse, who is stationed next to the nurse responsible for venipuncture, will open the envelope and specify the type of intervention before starting the venipuncture, Blinding description: In this study, the nurse who performs the venipuncture also applies the analgesic method to the child. The nurse who records clinical signs before and after venipuncture is unaware of the type of analgesia applied. The same nurse also gives the child the scale of pain that the child is supposed to grade. The film that is to be taken from the child's facial expressions will be taken by the pediatric resident, but the pain and anxiety will be scored by the presenter and the project partner separately and based on the film. However, both of them are not aware of the type of painless intervention in the patient who will be graded.</study_design>
      <phase>3</phase>
      <hc_freetext>Procedural pain and anxiety in children.</hc_freetext>
      <i_freetext>Intervention 1: Control group: 3 to 10 year olds need venipuncture for which no intervention is applied. Intervention 2: Intervention group 1:Melatonin drug under the brand name Nem Life is given to the child at a dose of half a milligram per kilogram of the child's body weight and a maximum of 5 mg orally, 30 minutes before venipunctur. Intervention 3: Intervention group 2: Midazolam ampoule with a dose of two tenths of a milligram per kilogram of body weight and a total volume of half a cc is used intranasally 15 minutes before inserting the intravenous line and once for the child. After administering the medicine in the nose, the nostril is kept closed for 30 seconds. Midazolam ampoule is produced by Kimidaro factory and is 5 mg. Intervention 4: Intervention group 3: Use of in-house distraction cards modeled after similar cards from Buzzy UK which are shown to the child 3 minutes before the venipuncture, and the co-nurse asks the child the questions on the back of the picture card that are related to the pictures and their details to distract her.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data except videos taken from a potential child can be shared after unidentified individuals.

When:
6 months after publishing the results

To whom:
Researchers working in academic and scientific institutions

Conditions:
For academic use by faculty members of universities in the country and around the world

Where to obtain:
Email to Dr. Minoo Saeidi at minoo.saeidi@gmail.com

How to obtain:
My email address is minoo.saeidi@gmail.com

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Minoo Saeidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Ave, Imam Hossein Children Hospital</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8195163381</zip>
        <telephone>+98 31 3386 6266</telephone>
        <email>minoo.saeidi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Minoo Saeidi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Ave</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8195163381</zip>
        <telephone>+98 31 3386 6266</telephone>
        <email>minoo.saeidi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Parental consent
No urgent need for venipuncture
3 to 10 years old childs</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>10 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Hearing and vision disorders that prevent the child from interacting
Dissatisfaction of parents to continue the study at any time during the intervention
Chronic or acute use of a sedative drug
The child has been taking painkillers, even acetaminophen, for the last 6 hours
Symptoms of a child's airway disorder
Patients with American Society of Anesthesiologists ’(ASA) classification from grade 3 upwards
Urgent need for venipuncture including decreased level of consciousness, shocks, severe respiratory distress, uncontrolled seizures, arrhythmia
Children at high risk for aspiration such as gastroesophageal reflux disease or gastrointestinal motility disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y84.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Medical procedure, unspecified as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: 3 to 10 year olds need venipuncture for which no intervention is applied</i_keyword>
      <i_keyword>Intervention group 1:Melatonin drug under the brand name Nem Life is given to the child at a dose of half a milligram per kilogram of the child's body weight and a maximum of 5 mg orally, 30 minutes before venipunctur</i_keyword>
      <i_keyword>Intervention group 2: Midazolam ampoule with a dose of two tenths of a milligram per kilogram of body weight and a total volume of half a cc is used intranasally 15 minutes before inserting the intravenous line and once for the child. After administering the medicine in the nose, the nostril is kept closed for 30 seconds. Midazolam ampoule is produced by Kimidaro factory and is 5 mg.</i_keyword>
      <i_keyword>Intervention group 3: Use of in-house distraction cards modeled after similar cards from Buzzy UK which are shown to the child 3 minutes before the venipuncture, and the co-nurse asks the child the questions on the back of the picture card that are related to the pictures and their details to distract her.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain caused by intravenous line insertion. Timepoint: Determining pain score during and after venipuncture. Method of measurement: Face, Legs, Activity, Cry, Consolability scale and Visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Child anxiety. Timepoint: Child's stress before and during intravenous line insertion. Method of measurement: Children's Emotional Manifestation Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-12-19</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan, Imam Khomeini Ave, Imam hossein children university hospital Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
